JAMA cardiology
Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.
Louisa A Mounsey, Mandana Chitsazan, Ivy Shi, Pedro H Ribeiro, Juhi K Parekh, Athar Roshandelpoor, Chiadi Ndumele, Norrina B Allen, Sadiya S Khan, Bruce M Psaty, James S Floyd, Daniel Levy, Rudolf A de Boer, Navin Suthahar, Kevin Damman
Published: 202610.1001/jamacardio.2025.5305
Abstract
Importance: The prevalence of obesity and cardiovascular-kidney-metabolic (CKM) syndrome continues to rise. Indications for novel CKM therapies, including glucagonlike peptide 1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter-2 inhibitors…
Preview only. Read the full abstract at the source